NEW YORK, May 2, 2016 /PRNewswire/ --
Q BioMed Inc. (QBIO), a biotechnology acceleration company announces that its technology partner Mannin Research Inc. will be
attending the Association for Research in Vision and Ophthalmology (ARVO), which takes place from May 1-5,
2016 in Seattle Washington. Mannin Research executives will be meeting with its vendors
and research partners. The meeting provides organizations the opportunity to further explore business development goals and other
collaborative opportunities for the MAN-01 program for treatment of glaucoma.
The ARVO annual meeting is the largest gathering of eye and vision researchers in the world. The annual meeting runs from
May 1st to 5th at the Washing State Convention Center in Seattle, Washington, attracting over 11,000 attendees from more than 75 countries.
Mannin's CEO, Dr. George N. Nikopoulos stated: "We are very pleased to be attending the
meeting. We are looking forward to engaging in meaningful research discussions and exploring possible collaboration opportunities
with other innovative groups in attendance."
In October 2015 Q BioMed Inc entered into an agreement with Mannin Research to exclusively
license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular
therapeutics. Mannin's primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and children,
using a research platform designed to help develop new drugs for that indication and cystic kidney disease, among other diseases.
Lead drug candidate MAN-01 is designed to treat abnormal vessels within the eye-thus treating glaucoma at its root causes.
We invite our shareholders and interested parties to subscribe to our email list and stay informed on our website at http://www.qbiomed.com and follow us on the social media feeds we use.
About Q BioMed Inc.
Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion
capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock price. Factors that could cause actual results to differ
materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research
and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and
relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability
to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any
forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
SOURCE Q BioMed Inc